Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 30 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2017 Planned primary completion date changed from 3 Aug 2017 to 3 Aug 2018.
- 13 Apr 2017 Planned End Date changed from 3 Apr 2018 to 3 Aug 2018.